A detailed history of Scholtz & Company, LLC transactions in Vericel Corp stock. As of the latest transaction made, Scholtz & Company, LLC holds 50,573 shares of VCEL stock, worth $1.7 Million. This represents 0.96% of its overall portfolio holdings.

Number of Shares
50,573
Previous 50,119 0.91%
Holding current value
$1.7 Million
Previous $2.24 Million 3.8%
% of portfolio
0.96%
Previous 1.13%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 04, 2025

BUY
$37.92 - $45.7 $17,215 - $20,747
454 Added 0.91%
50,573 $2.15 Million
Q1 2025

May 15, 2025

BUY
$44.5 - $61.8 $2.23 Million - $3.1 Million
50,119 New
50,119 $2.24 Million
Q4 2024

Feb 12, 2025

BUY
$40.05 - $59.11 $1.91 Million - $2.82 Million
47,660 New
47,660 $2.62 Million
Q3 2024

Nov 12, 2024

BUY
$42.25 - $53.56 $571,431 - $724,399
13,525 Added 45.73%
43,098 $1.82 Million
Q2 2024

Aug 08, 2024

BUY
$41.71 - $52.9 $1.23 Million - $1.56 Million
29,573 New
29,573 $1.36 Million

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $1.58B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Scholtz & Company, LLC Portfolio

Follow Scholtz & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scholtz & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Scholtz & Company, LLC with notifications on news.